🇧🇪 ARGX.BR — argenx SE

Salud Compra fuerte
← Volver

Precio actual

815,80 EUR

Máx. histórico

912,40

64 días

Caída desde máximo

-10,59%

Rango 52 semanas

568,40 – 925,00

Variación hoy

+0,03%

Cierre anterior

815,60

Rango de hoy

788,80 – 815,80

Volumen hoy

102.849

Peor caída histórica

-39,26%

21/07/2023 → 21/12/2023

Recuperado en 262 días

Volatilidad anualizada ⓘ

43,77%

Información
Nombre completo
argenx SE
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
1.863
PER ⓘ
32,83 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
1.005,32 EUR (puede no estar actualizado)
Primera cotización
10/07/2014
Precio actualizado
hace 1 día
Sobre la empresa

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
11/12/2015 9,79 9,80 9,70 9,75 +0,00% 1,02% 910
10/12/2015 9,86 9,86 9,10 9,75 +0,00% 7,71% 2.866
09/12/2015 9,75 9,75 9,60 9,75 +1,04% 1,54% 1.025
08/12/2015 9,75 9,85 9,65 9,65 -1,03% 2,05% 1.707
07/12/2015 9,85 9,89 9,75 9,75 +0,00% 1,42% 3.946
04/12/2015 9,79 9,85 9,72 9,75 -0,20% 1,33% 15.303
03/12/2015 9,84 9,85 9,77 9,77 -0,61% 0,81% 1.160
02/12/2015 9,82 9,83 9,82 9,83 +0,10% 0,10% 1.535
01/12/2015 9,67 9,82 9,66 9,82 +3,37% 1,65% 8.010
30/11/2015 9,39 9,50 9,39 9,50 +1,82% 1,17% 6.709
27/11/2015 9,32 9,39 9,32 9,33 +0,11% 0,75% 1.106
26/11/2015 9,30 9,39 9,30 9,32 +0,32% 0,97% 2.430
25/11/2015 9,39 9,39 9,28 9,29 -0,32% 1,17% 837
24/11/2015 9,34 9,34 9,13 9,32 +1,41% 2,25% 42.758
23/11/2015 9,07 9,25 9,07 9,19 +0,99% 1,98% 46.145
20/11/2015 9,05 9,17 9,03 9,10 +0,55% 1,55% 9.748
19/11/2015 9,20 9,20 9,05 9,05 +0,00% 1,63% 3.993
18/11/2015 9,10 9,10 9,05 9,05 -0,11% 0,55% 1.629
17/11/2015 9,04 9,17 9,04 9,06 +0,11% 1,44% 6.638
16/11/2015 9,20 9,28 9,05 9,05 -2,58% 2,50% 10.267
13/11/2015 9,13 9,32 9,13 9,29 +1,42% 2,08% 2.040
12/11/2015 9,12 9,24 9,12 9,16 -0,87% 1,32% 1.484
11/11/2015 9,05 9,24 9,05 9,24 +1,54% 2,10% 5.128
10/11/2015 9,35 9,35 9,05 9,10 -0,87% 3,21% 5.888
09/11/2015 9,20 9,34 9,07 9,18 -0,43% 2,93% 11.750
06/11/2015 9,20 9,33 9,20 9,22 -0,75% 1,41% 2.504
05/11/2015 9,20 9,29 9,20 9,29 +0,87% 0,98% 543
04/11/2015 9,05 9,32 9,05 9,21 +1,77% 2,98% 4.826
03/11/2015 8,80 9,15 8,80 9,05 +2,26% 3,98% 3.965
02/11/2015 8,98 8,98 8,85 8,85 -1,45% 1,45% 2.052